Found: 401
Select item for more details and to access through your institution.
Management of Patients with HIV and Hepatitis B Coinfection.
- Published in:
- Journal of Clinical Outcomes Management, 2017, v. 24, n. 10, p. 469
- By:
- Publication type:
- Article
Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir.
- Published in:
- Infection, 2020, v. 48, n. 2, p. 213, doi. 10.1007/s15010-019-01376-5
- By:
- Publication type:
- Article
Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI.
- Published in:
- Infection, 2018, v. 46, n. 5, p. 599, doi. 10.1007/s15010-018-1171-z
- By:
- Publication type:
- Article
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
- Published in:
- Infection, 2017, v. 45, n. 4, p. 521, doi. 10.1007/s15010-017-1018-z
- By:
- Publication type:
- Article
Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database.
- Published in:
- Infection, 2015, v. 43, n. 3, p. 339, doi. 10.1007/s15010-015-0764-z
- By:
- Publication type:
- Article
Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.
- Published in:
- Infection, 2012, v. 40, n. 3, p. 311, doi. 10.1007/s15010-011-0237-y
- By:
- Publication type:
- Article
What´s hot in European Journal of Pharmaceutics and Biopharmaceutics?
- Published in:
- TechnoPharm, 2017, v. 7, n. 4, p. 52
- By:
- Publication type:
- Article
POLYMORPHIC STABILITY EVALUATION OF DARUNAVIR AND RITONAVIR IN FIXED DOSE DRUG COMBINATION PRODUCT BY X-RAY DIFFRACTION AND DIFFERENTIAL SCANNING CALORIMETRY TECHNIQUES.
- Published in:
- Indian Drugs, 2023, v. 60, n. 3, p. 53, doi. 10.53879/id.60.03.13686
- By:
- Publication type:
- Article
A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 11, p. 1, doi. 10.1093/ofid/ofad542
- By:
- Publication type:
- Article
Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Hypersensitivity and Desensitization to Darunavir in a Case of HIV Infection with Triple-Class Drug Resistance: Case Description and Review of the Literature.
- Published in:
- 2013
- By:
- Publication type:
- Case Study
Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.
- Published in:
- Scientific Reports, 2015, p. 10517, doi. 10.1038/srep10517
- By:
- Publication type:
- Article
Revealing Origin of Decrease in Potency of Darunavir and Amprenavir against HIV-2 relative to HIV-1 Protease by Molecular Dynamics Simulations.
- Published in:
- Scientific Reports, 2014, p. 1, doi. 10.1038/srep06872
- By:
- Publication type:
- Article
Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug darunavir.
- Published in:
- Applied Nanoscience, 2017, v. 7, n. 1/2, p. 47, doi. 10.1007/s13204-017-0547-1
- By:
- Publication type:
- Article
Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS.
- Published in:
- HIV/AIDS - Research & Palliative Care, 2016, v. 8, p. 175, doi. 10.2147/HIV.S56158
- By:
- Publication type:
- Article
Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection.
- Published in:
- HIV/AIDS - Research & Palliative Care, 2016, v. 8, p. 47, doi. 10.2147/HIV.S99063
- By:
- Publication type:
- Article
Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 5, p. 427, doi. 10.1007/s40273-013-0048-3
- By:
- Publication type:
- Article
Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France.
- Published in:
- PharmacoEconomics, 2010, v. 28, p. 183, doi. 10.2165/11587520-000000000-00000
- By:
- Publication type:
- Article
Costs to Achieve Undetectable HIV RNA with Darunavir-Containing Highly Active Antiretroviral Therapy in Highly Pretreated Patients: The POWER Experience.
- Published in:
- PharmacoEconomics, 2010, v. 28, p. 69, doi. 10.2165/11587460-000000000-00000
- By:
- Publication type:
- Article
US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial.
- Published in:
- PharmacoEconomics, 2010, v. 28, p. 129, doi. 10.2165/11587490-000000000-00000
- By:
- Publication type:
- Article
Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK.
- Published in:
- PharmacoEconomics, 2010, v. 28, p. 107, doi. 10.2165/11587480-000000000-00000
- By:
- Publication type:
- Article
Cost Effectiveness of Darunavir/Ritonavir in Highly Treatment-Experienced, HIV-1-Infected Adults in the USA.
- Published in:
- PharmacoEconomics, 2010, v. 28, p. 83, doi. 10.2165/11587470-000000000-00000
- By:
- Publication type:
- Article
Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor-Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and the UK.
- Published in:
- PharmacoEconomics, 2010, v. 28, p. 147, doi. 10.2165/11587500-000000000-00000
- By:
- Publication type:
- Article
A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection.
- Published in:
- PharmacoEconomics, 2010, v. 28, p. 1, doi. 10.2165/11587410-000000000-00000
- By:
- Publication type:
- Article
Pharmacokinetic Outcomes of the Interactions of Antiretroviral Agents with Food and Supplements: A Systematic Review and Meta-Analysis.
- Published in:
- Nutrients, 2022, v. 14, n. 3, p. 520, doi. 10.3390/nu14030520
- By:
- Publication type:
- Article
Patient Satisfaction with Once-Daily Single-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (DRV/c/FTC/TAF): A Real-World Study of Patient Self-Reported Outcomes in HIV-1–Diagnosed Adults.
- Published in:
- Patient Preference & Adherence, 2022, v. 16, p. 83, doi. 10.2147/PPA.S332555
- By:
- Publication type:
- Article
Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide.
- Published in:
- Patient Preference & Adherence, 2020, v. 14, p. 2315, doi. 10.2147/PPA.S272211
- By:
- Publication type:
- Article
Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial.
- Published in:
- PLoS ONE, 2019, v. 14, n. 1, p. 1, doi. 10.1371/journal.pone.0209911
- By:
- Publication type:
- Article
Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
- Published in:
- PLoS ONE, 2019, v. 14, n. 1, p. 1, doi. 10.1371/journal.pone.0210476
- By:
- Publication type:
- Article
Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients.
- Published in:
- PLoS ONE, 2018, v. 13, n. 4, p. 1, doi. 10.1371/journal.pone.0196257
- By:
- Publication type:
- Article
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
- Published in:
- PLoS ONE, 2017, v. 12, n. 11, p. 1, doi. 10.1371/journal.pone.0187393
- By:
- Publication type:
- Article
Effectiveness of tipranavir versus darunavir as a salvage therapy in HIV-1 treatment-experienced patients.
- Published in:
- Journal of Infection in Developing Countries, 2016, v. 10, n. 9, p. 982, doi. 10.3855/jidc.6629
- By:
- Publication type:
- Article
Outcomes of Bariatric Surgery in People With Human Immunodeficiency Virus: A Retrospective Analysis From the ATHENA Cohort.
- Published in:
- Clinical Infectious Diseases, 2023, v. 77, n. 11, p. 1561, doi. 10.1093/cid/ciad404
- By:
- Publication type:
- Article
Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s.
- Published in:
- Clinical Infectious Diseases, 2022, v. 74, n. 5, p. 857, doi. 10.1093/cid/ciab542
- By:
- Publication type:
- Article
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment–Experienced People Living With Human Immunodeficiency Virus.
- Published in:
- Clinical Infectious Diseases, 2021, v. 73, n. 7, p. e2323, doi. 10.1093/cid/ciaa1878
- By:
- Publication type:
- Article
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 12, p. 3110, doi. 10.1093/cid/ciz1213
- By:
- Publication type:
- Article
Erratum to: Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 11, p. 3020, doi. 10.1093/cid/ciaa534
- Publication type:
- Article
Food Insecurity Is Associated With Lower Levels of Antiretroviral Drug Concentrations in Hair Among a Cohort of Women Living With Human Immunodeficiency Virus in the United States.
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 6, p. 1517, doi. 10.1093/cid/ciz1007
- By:
- Publication type:
- Article
Once-daily Doravirine in Human Immunodeficiency Virus Type 1–Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis.
- Published in:
- Clinical Infectious Diseases, 2020, v. 70, n. 7, p. 1344, doi. 10.1093/cid/ciz424
- By:
- Publication type:
- Article
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus–1: An Integrated Safety Analysis.
- Published in:
- Clinical Infectious Diseases, 2020, v. 70, n. 7, p. 1336, doi. 10.1093/cid/ciz423
- By:
- Publication type:
- Article
Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus.
- Published in:
- Clinical Infectious Diseases, 2019, v. 69, n. 7, p. 1254, doi. 10.1093/cid/ciz121
- By:
- Publication type:
- Article
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.
- Published in:
- Clinical Infectious Diseases, 2019, v. 68, n. 7, p. 1184, doi. 10.1093/cid/ciy589
- By:
- Publication type:
- Article
Drug–Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
- Published in:
- Clinical Infectious Diseases, 2018, v. 67, n. 6, p. 934, doi. 10.1093/cid/ciy201
- By:
- Publication type:
- Article
Antiretrovirals inhibit arginase in human microglia.
- Published in:
- Journal of Neurochemistry, 2016, v. 136, n. 2, p. 363, doi. 10.1111/jnc.13393
- By:
- Publication type:
- Article
Minimal effects of Darunavir on adipocyte differentiation and metabolism in 3T3-L1 cells.
- Published in:
- Journal of Infection & Chemotherapy (Springer Science & Business Media B.V.), 2012, v. 18, n. 4, p. 485, doi. 10.1007/s10156-011-0361-8
- By:
- Publication type:
- Article
Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.
- Published in:
- Journal of Infection & Chemotherapy (Springer Science & Business Media B.V.), 2011, v. 17, n. 1, p. 105, doi. 10.1007/s10156-010-0082-4
- By:
- Publication type:
- Article
Servicio de dispensación: interacción entre darunavir y quetiapina.
- Published in:
- Farmacéuticos Comunitarios, 2022, v. 14, n. 4, p. 38, doi. 10.33620/FC.2173-9218.(2022/Vol14).004.06
- By:
- Publication type:
- Article
Efficacy and safety of darunavir (Prezista®) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, onecohort, non-interventional, prospective study
- Published in:
- Germs, 2014, v. 4, n. 3, p. 59, doi. 10.11599/germs.2014.1057
- By:
- Publication type:
- Article
Daily ritonavir‐boosted darunavir for viral suppression in pregnancy (DRV‐P).
- Published in:
- HIV Medicine, 2024, v. 25, n. 1, p. 129, doi. 10.1111/hiv.13546
- By:
- Publication type:
- Article
Immune response to ART initiation in advanced HIV infection.
- Published in:
- HIV Medicine, 2023, v. 24, n. 6, p. 716, doi. 10.1111/hiv.13467
- By:
- Publication type:
- Article